Ad5-yCD/mutTK(SR39)rep-ADP

AXP000047.1 · Oncolytic virus

Platform
adenovirus (Ad5, replication-competent, ADP-overexpressing)
Originator
Henry Ford Health
Sponsor
Henry Ford Health

Names

NameTypeSource
Ad5-yCD/mutTK(SR39)rep-ADPpreferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (yCD/mutTK(SR39)rep-ADP)
Replication
replicating
Modifications
replication-competent Ad5 with restored adenovirus death protein; E1B-55kDa retained
Transgenes
yCD/mutTK(SR39) suicide-gene fusion, adenovirus death protein (ADP)
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C88330

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT05686798Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.RecruitingPhase 12022-11-292027-0118Astrocytoma; Brain Cancer; Brain Tumor; GBM; Glioblastoma; Glioblastoma Multiforme; Glioma; Malignant Astrocytoma; Malignant Glioma of Brain
NCT03029871Oncolytic Adenovirus-Mediated Gene Therapy for Lung CancerWithdrawnPhase 12017-01-132018-12-310Non-small Cell Lung Cancer Stage I

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 32084409Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial.Gastrointestinal endoscopy2020name in abstract: Ad5-yCD/mutTK(SR39)rep-ADP

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 17551507Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer.Molecular therapy : the journal of the American Society of Gene Therapy2007name in abstract: Ad5-yCD/mutTK(SR39)rep-ADP
PMID 16290236Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.Molecular therapy : the journal of the American Society of Gene Therapy2006name in abstract: Ad5-yCD/mutTK(SR39)rep-ADP

Notes

Second-generation Henry Ford construct: yeast cytosine deaminase/mutant HSV-1 thymidine kinase (SR39) fusion suicide gene plus restored adenovirus death protein, used with 5-FC and valganciclovir and with radiotherapy. Trials in prostate cancer, pancreatic cancer and brain metastases (NCT03029871, NCT05686798).

How to cite

Ad5-yCD/mutTK(SR39)rep-ADP (AXP000047.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000047.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.